We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
+0.71%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$197M
AUM Growth
-$53.3M
Cap. Flow
-$49.4M
Cap. Flow %
-25.12%
Top 10 Hldgs %
100%
Holding
6
New
–
Increased
–
Reduced
1
Closed
1

Top Buys

No buys this quarter

Top Sells

Rank Stock Value
1
IFRX icon
InflaRx
IFRX
+$27.7M
2
DRNA
Dicerna Pharmaceuticals, Inc.
DRNA
+$21.8M

Sector Composition

Rank Sector Weight
1 Healthcare 30.73%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
DRNA
1
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$115M 58.64%
7,330,237
-1,600,000
-18% -$21.8M
REPL icon
2
Replimune Group
REPL
$1.03B
$41.6M 21.14%
2,838,968
– –
MRNS
3
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$20.9M 10.63%
1,260,684
– –
SLDB icon
4
Solid Biosciences
SLDB
$826M
$11.4M 5.81%
132,630
– –
APTX
5
DELISTED
Aptinyx Inc. Common Stock
APTX
$7.43M 3.78%
2,225,092
– –
IFRX icon
6
InflaRx
IFRX
$272M
– –
-732,670
Closed -$27.7M

Similar funds

SL
Sentinus LLC Oak Brook, Illinois $1.11B AUM 17.13% 1-Year Est. Return
JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
RWM
RKL Wealth Management Lancaster, Pennsylvania $1.11B AUM 18.99% 1-Year Est. Return
EIA
Emerald Investment Advisers Leola, Pennsylvania $1.11B AUM
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return

Bain Capital Life Sciences Investors's Q2 2019 Portfolio in Review

As of Q2 2019, Bain Capital Life Sciences Investors held 6 positions worth $197M, down 21% from $250M the previous quarter. Its ten largest holdings account for 100% of the portfolio.

Bain Capital Life Sciences Investors withdrew a net $49.4M in Q2 2019, closing 1 position and reducing 1 holding. Its most notable exit was InflaRx, an estimated $27.7M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, down from 39% a quarter earlier.

  • Bain Capital Life Sciences Investors's biggest Q2 2019 reduction was Dicerna Pharmaceuticals, Inc., cutting an estimated $21.8M.
  • Bain Capital Life Sciences Investors fully exited InflaRx in Q2 2019, selling an estimated $27.7M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 100% of its $197M portfolio in Q2 2019.
  • Bain Capital Life Sciences Investors opened 0 new positions and closed 1 in Q2 2019.
  • Bain Capital Life Sciences Investors's portfolio value fell 21% quarter-over-quarter to $197M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q2 2019, filed 14 Aug 2019.